{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T22:59:47Z","timestamp":1781564387831,"version":"3.54.5"},"reference-count":16,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:00:00Z","timestamp":1702339200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["aaceclinicalcasereports.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["AACE Clinical Case Reports"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.aace.2023.12.003","type":"journal-article","created":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T12:06:52Z","timestamp":1702728412000},"page":"49-51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["A Woman With HNF1A-Associated Monogenic Diabetes Treated Successfully With Repaglinide Monotherapy"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4438-1047","authenticated-orcid":false,"given":"Katherine","family":"Cuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilana R.","family":"Bass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.aace.2023.12.003_bib1","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/j.1365-2265.2011.04049.x","article-title":"Who should have genetic testing for maturity-onset diabetes of the young?","volume":"75","author":"Naylor","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.aace.2023.12.003_bib2","series-title":"GeneReviews\u00ae","article-title":"Maturity-onset diabetes of the young overview","author":"Naylor","year":"2018"},{"issue":"7","key":"10.1016\/j.aace.2023.12.003_bib3","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/dme.12992","article-title":"Successful maintenance on sulphonylurea therapy and low diabetes complication rates in a HNF1A-MODY cohort","volume":"33","author":"Bacon","year":"2016","journal-title":"Diabet Med"},{"issue":"9392","key":"10.1016\/j.aace.2023.12.003_bib4","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S0140-6736(03)14571-0","article-title":"Genetic cause of hyperglycaemia and response to treatment in diabetes","volume":"362","author":"Pearson","year":"2003","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.aace.2023.12.003_bib5","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/humu.22279","article-title":"Mutations in the genes encoding the transcription factors hepatocyte nuclear factor 1 alpha and 4 alpha in maturity-onset diabetes of the young and hyperinsulinemic hypoglycemia","volume":"34","author":"Colclough","year":"2013","journal-title":"Hum Mutat"},{"issue":"12","key":"10.1016\/j.aace.2023.12.003_bib6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s11892-018-1111-4","article-title":"Genetics of monogenic diabetes: present clinical challenges","volume":"18","author":"Misra","year":"2018","journal-title":"Curr Diab Rep"},{"issue":"6","key":"10.1016\/j.aace.2023.12.003_bib7","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.3390\/ijms23063222","article-title":"HNF1A mutations and beta cell dysfunction in diabetes","volume":"23","author":"Miyachi","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1016\/j.aace.2023.12.003_bib8","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.2337\/diabetes.54.11.3065","article-title":"Diabetes and insulin secretion: the ATP-sensitive K+ channel (K ATP) connection","volume":"54","author":"Koster","year":"2005","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.aace.2023.12.003_bib9","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s001250050956","article-title":"Hyperexcitability to sulphonylurea in MODY3","volume":"41","author":"S\u00f8vik","year":"1998","journal-title":"Diabetologia"},{"issue":"7","key":"10.1016\/j.aace.2023.12.003_bib10","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1046\/j.1464-5491.2000.00305.x","article-title":"Sensitivity to sulphonylureas in patients with hepatocyte nuclear factor-1alpha gene mutations: evidence for pharmacogenetics in diabetes","volume":"17","author":"Pearson","year":"2000","journal-title":"Diabet Med"},{"issue":"3","key":"10.1016\/j.aace.2023.12.003_bib11","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2337\/diabetes.47.3.345","article-title":"Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes","volume":"47","author":"Fuhlendorff","year":"1998","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.aace.2023.12.003_bib12","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2337\/diacare.29.02.06.dc05-1314","article-title":"Improved prandial glucose control with lower risk of hypoglycemia with nateglinide than with glibenclamide in patients with maturity-onset diabetes of the young type 3","volume":"29","author":"Tuomi","year":"2006","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.aace.2023.12.003_bib13","doi-asserted-by":"crossref","first-page":"e775","DOI":"10.1542\/peds.2012-2537","article-title":"Meglitinide analogues in adolescent patients with HNF1A-MODY (MODY 3)","volume":"133","author":"Becker","year":"2014","journal-title":"Pediatrics"},{"issue":"7","key":"10.1016\/j.aace.2023.12.003_bib14","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.2337\/dc13-3007","article-title":"Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist: a double-blind, randomized, crossover trial","volume":"37","author":"\u00d8stoft","year":"2014","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.aace.2023.12.003_bib15","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1210\/js.2019-00278","article-title":"Optimal glycemic control in a patient with HNF1A MODY with GLP-1 RA monotherapy: implications for future therapy","volume":"3","author":"Fantasia","year":"2019","journal-title":"J\u00a0Endocr Soc"},{"issue":"4","key":"10.1016\/j.aace.2023.12.003_bib16","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1089\/dia.2009.0159","article-title":"Dipeptidyl peptidase-IV inhibitors are efficient adjunct therapy in HNF1A maturity-onset diabetes of the young patients--report of two cases","volume":"12","author":"Katra","year":"2010","journal-title":"Diabetes Technol Ther"}],"container-title":["AACE Clinical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2376060523001724?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2376060523001724?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T08:15:34Z","timestamp":1710749734000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2376060523001724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2376060523001724"],"URL":"https:\/\/doi.org\/10.1016\/j.aace.2023.12.003","relation":{},"ISSN":["2376-0605"],"issn-type":[{"value":"2376-0605","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Woman With HNF1A-Associated Monogenic Diabetes Treated Successfully With Repaglinide Monotherapy","name":"articletitle","label":"Article Title"},{"value":"AACE Clinical Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aace.2023.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 AACE. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}